View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Kris Kippers
  • Kris Kippers

Proximus - Fiber talks ongoing with both Telenet & OBEL

• Local press article stating that Proximus aims for a fiber deal with Wyre• With the May 15 deadline approaching, more should come in due course• Any reduction in fiber capex is positive for the investment case - BUY

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

CTP: An excellent start to the year. Proximus: Completes acquisition of 83% stake in Route Mobile

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Lynn Hautekeete
  • Michiel Declercq
  • Thomas Vranken
  • Wim Lewi
Kris Kippers
  • Kris Kippers

Proximus - Completion of the Route Mobile transaction

• Following regulatory clearing, Proximus announced the closing of the Route Mobile transaction• Post-reinvestment of Route Mobile shareholders, the net cash out for Proximus would be EUR 634m. A webcast will be organized on June 3• We stick to our BUY rating and EUR 11.0 TP, DCF-based

Hilde Van Boxstael ... (+8)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Morning Notes : ABI BB, AD NA, BEKB BB, EURN BB, GBLB BB, MONT BB, SOL...

: ABI BB, AD NA, BEKB BB, EURN BB, GBLB BB, MONT BB, SOLB BB, MAAT FP

Wim Hoste
  • Wim Hoste

Solvay Model update post 1Q, reconfirming our BUY rating

We upped our FY24 adjusted EBITDA forecast by 2% following the better than expected 1Q24 results. After the recent spun off of Syensqo, Solvay is a base chemicals group with leading market and technology positions in the vast majority of its businesses. The company will be managed with a conservative financial approach, favouring dividends over aggressive growth and operating with a solid balance sheet (1.4x leverage). The stable to growing dividend flow implies a solid 7% dividend yield. Other ...

Wim Hoste
  • Wim Hoste

Solvay Conference call feedback

Below are the highlights from the conference call. 1Q underlying EBITDA dropped by 13.6% organically to 265m which was 13% better than our forecast and 12% above CSS. Solvay reiterated its FY uEBITDA guidance which calls for a 10-20% organic decline vs the restated 2023 base. After the recent spun off of Syensqo, Solvay is a base chemicals group with leading market and technology positions in the vast majority of its businesses. The company will be managed with a conservative financial approach...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Adecco: 1Q24 in line; stable trends into 2Q24. Arcadis: Interesting contract in Ontario. NSI: Further comments on the First Sponsor move. Philips: Healthineers reports 2Q24 update. Solvay: Solid 1Q24 EBITDA beat, FY consensus looks rather cautious now

Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Sharad Kumar S.P
  • Wim Hoste
  • Wim Lewi
Stefano Toffano
  • Stefano Toffano

Solvay : A solid quarter despite the large net pricing headwinds

>Pressure on underlying EBITDA less than expected - A good first set of results for the new Solvay, with Q1 24 group revenues of € 1,201m (+6% vs ccs) reflecting -11.9% yoy organic growth mainly as a consequence of lower prices (-14.5% yoy), partially offset by higher volumes (+2.5% yoy). Q1 24 underlying EBITDA came in much stronger than expected at € 265m (-27.2% yoy, -13.6% organically given the exit from the thermal insulation and energy third parties operations) ...

Wim Hoste
  • Wim Hoste

Solvay FIRST LOOK: 1Q underlying EBITDA beat, FY guidance maintained

1Q underlying EBITDA dropped by 13.6% organically to 265m which was 13% better than our forecast and 12% above CSS. Solvay reiterated its FY uEBITDA guidance which calls for a 10-20% organic decline vs the restated 2023 base. After the recent spun off of Syensqo, Solvay is a base chemicals group with leading market and technology positions in the vast majority of its businesses. The company will be managed with a conservative financial approach, favouring dividends over aggressive growth and op...

 PRESS RELEASE

Solvay first quarter 2024 results

Solvay first quarter 2024 results Strong FCF supported by resilient EBITDA and discipline on costs and capex Brussels, May 7, 2024 – 7:00 am CEST   -  regulated information Highlights Net sales for Q1 2024 at €1,201 million were down -11.9% organically versus Q1 2023, with positive volume impact, for the first time in seven quarters, in both Basic and Performance Chemicals segments. Prices decreased, mostly reflecting the lower energy and raw material costs.Underlying EBITDA of €265 million for the first quarter was -13.6% lower organically compared to a high Q1 2023, with negative Net ...

 PRESS RELEASE

Résultats du premier trimestre 2024

Résultats du premier trimestre 2024 Information réglementée Un FCF solide soutenu par un EBITDA résilient et la gestion maîtrisée des coûts et des investissements Bruxelles, le 7 mai 2024 à 7h00 CEST - information réglementée Faits marquants Le chiffre d'affaires net du T1 2024 s’élève à €1 201 millions, en baisse organique de -11,9% par rapport au T1 2023, avec un impact positif des volumes pour la première fois en sept trimestres, visible à la fois dans les segments Basic Chemicals et Performance Chemicals. Les prix diminuent, reflétant principalement la baisse des coûts de l'énergie...

 PRESS RELEASE

Resultaten Solvay van het eerste kwartaal 2024

Resultaten Solvay van het eerste kwartaal 2024 Gereglementeerde informatie Sterke vrije kasstroom ondersteund door veerkrachtige EBITDA en beheersing van kosten en investeringen Brussel, 7 mei 2024, om 7u00 CEST -  gereglementeerde informatie Hoogtepunten De netto-omzet voor Kw1 2024 van €1 201 miljoen daalde op organische basis met -11,9% ten opzichte van Kw1 2023, met een positieve volume-impact, voor het eerst in zeven kwartalen, in zowel de segmenten Basic Chemicals als Performance Chemicals. De prijzen daalden, vooral door lagere energie- en grondstofkosten.De onderliggende EBITDA...

Frank Claassen
  • Frank Claassen

Solvay - Resilience and return of volume growth

•    Q1-24 EBITDA was more than 10% above our and consensus estimates, supported by the return of positive volume growth. •    This confirms our view that Solvay is resilient, also due to its strong cost and capex discipline.•    Valuation multiples remain very attractive for a 20% ROCE business. We stick our Buy and TP of EUR 36, based on our 2025E SOTP.

Jerôme Bodin
  • Jerôme Bodin

ODDO BHF Small & MIDCAP MORNING NEWS - 03/05/2024

Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...

Jerôme Bodin
  • Jerôme Bodin

ODDO BHF Small & MIDCAP MORNING NEWS - 05/03/2024

Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures

Galapagos : Largely unsurprising numbers

>Solid cash position - Galapagos reported its Q1 earnings after the close in the US. Group revenues came in at € 100m vs € 83m expected. The bulk stemmed from its agreement with Gilead for € 62m while net product sales amounted to € 37m. At the operating level, costs were broadly under control, with total expenditure of around € 129m vs € 110m although we note an increase of close to 36% in R&D expense due to the development of the clinical portfolio. In contrast...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch